OptiBiotix Health PLC SweetBiotix® development: human taste studies (5937C)
23 January 2018 - 6:00PM
UK Regulatory
TIDMOPTI
RNS Number : 5937C
OptiBiotix Health PLC
23 January 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
SweetBiotix(R) development: Results of further human taste
studies
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol and diabetes, announces successful human taste
studies in its SweetBiotix(R) product development programmes. The
Company has a number of development programmes designed to:-
1. Develop natural high intensity sweeteners (HIS) with improved
flavour profile and microbiome modulating functionality. OptiBiotix
announced on July 11(th) 2017 that it had succeeded in developing
customised oligosaccharides demonstrating good flavour profile and
sweetness of between 140X and 223X that of sucrose at equivalent
concentrations.
2. Develop sweet natural healthy fibres which are not digested
in the human gut, and hence calorie free. These sweet fibres have
been developed as potential bulk sugar replacements as a product
which has sweetness similar to sucrose but contain no calories, and
improve microbiome diversity.
This announcement reports on human taste studies carried out on
OptiBiotix's sweet healthy natural fibres compared to existing
sugars and prebiotics. The studies were performed by The Flavour
and Sensory Science Centre at the University of Reading and tested
eight samples (including OptiBiotix's test sample) using an expert
panel of 11 experienced panellists who rated 11 attributes compared
to sucrose. The tests showed:-
-- Of the 11 attributes rated, eight were significantly
different between samples. The most substantial differences were in
sweet taste, strength of off-flavour and sweet after taste.
-- The sweet oligosaccharide developed by OptiBiotix was
significantly sweeter than all other samples and low in all
off-flavours (e.g. bitterness, sourness, staleness, saltiness
etc).
The results of this independent study provide proof of product
concept for natural, low calorie, sweet healthy fibres with gut
microbiome functionality as potential bulk sugar replacement in a
wide range of food products.
Given the global sweetener market, currently dominated by sugar,
is forecast to reach $112bn by 2022 (Mordor Intelligence, 2017),
the Company is filing additional patents to add a further layer of
protection to the existing intellectual property portfolio to
protect its inventions and fully exploit the commercial potential
with suitable industry partners.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased
with the results of this study which showed OptiBiotix's sweet
oligosaccharide had the highest sweetness and was low in
off-flavours when compared to a wide range of existing sugars and
prebiotics. This development creates the potential to replace
existing 'unhealthy' sugars with low calorie, healthy
non-digestible fibres (SweetBiotix(R)) with gut microbiome
functionality. With growing concerns over the impact on health of
traditional sugars and artificial sweeteners, the ability to
develop sweet functional fibres puts OptiBiotix at the forefront of
product development in this area of growing industry and commercial
interest."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESFKBDNCBKDPDB
(END) Dow Jones Newswires
January 23, 2018 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024